Compare CTM & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | PLRX |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.7M | 81.1M |
| IPO Year | 2022 | 2020 |
| Metric | CTM | PLRX |
|---|---|---|
| Price | $0.72 | $1.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $3.00 | $2.67 |
| AVG Volume (30 Days) | ★ 1.2M | 510.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,866,001.00 | N/A |
| Revenue This Year | $20.36 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $0.48 | $1.09 |
| 52 Week High | $1.56 | $1.95 |
| Indicator | CTM | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 49.09 |
| Support Level | $0.48 | $1.12 |
| Resistance Level | $1.21 | $1.38 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 86.77 | 59.09 |
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.